Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Clinical trial NCT01751425 · TERMINATED

Trial details

NCT number: NCT01751425
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission Minimal Residual Disease Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Start date: 2013-07-24
Primary completion: 2019-09-24
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.